Use of Phosphazene
Base BTPP for Phosphorylative Activation
in the Scale-Up of BET Inhibitor GSK525762
Posted on 2022-08-18 - 15:20
In this article, an improved synthesis of a key triazole
intermediate
in the synthesis of bromo- and extra-terminal domain (BET) inhibitor
GSK525762 (1) is described, which avoids the need for
the formation of a thioamide intermediate for the key methyltriazolo[1,4]benzodiazapine
formation. Conditions for a phosphorylative activation of lactam 4 were identified through the extensive screening of reagents
and solvents, where a number of phosphazene bases were found to have
unmatched activity. Development efforts focused on the use of phosphazene
base P1-t-Bu-tris(tetramethylene) (BTPP) with diethyl
chlorophosphoridate (DECP) and culminated in the demonstration of
the new process at a 750 g scale. The resulting synthetic route avoids
the use of thiolating agent P2S5 and isolation
of the resulting thioamide while delivering 1 in exceptional
purity with a reduced number of steps, resulting in a higher yield
and improved throughput over the previous process.
CITE THIS COLLECTION
DataCiteDataCite
No result found
Jones, Rhiannon E. H.; Aspin, Peter; Davies, Suzanne H.; Mann, Inderjit; Priestley, Catherine; Roberts, Andrew D.; et al. (2022). Use of Phosphazene
Base BTPP for Phosphorylative Activation
in the Scale-Up of BET Inhibitor GSK525762. ACS Publications. Collection. https://doi.org/10.1021/acs.oprd.2c00048